A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants
Latest Information Update: 30 Oct 2024
At a glance
- Drugs V-350A (Primary) ; V-350B (Primary)
- Indications Epstein-Barr virus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 30 Oct 2024 New trial record